Biosense Webster News & Events

VARIPULSE™

The Evolving Landscape of Atrial Fibrillation Ablation: VARIPULSE™ Launches in European Hospitals

22 October 2024

Johnson & Johnson MedTech receives CE Mark for OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

Biosense Webster Completes Enrollment of Omny-IRE Clinical Trial Investigating the OMNYPULSE™ Large-tip Focal Pulsed Field Ablation Catheter

How Our Innovation Restored an Employee’s Heartbeat

How Our Innovation Restored an Employee’s Heartbeat

Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress

Biosense Webster inspIRE clinical study demonstrates 80% freedom from atrial arrhythmia recurrence at 12 months

VARIPULSE Platform

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

29 February 2024

VARIPULSE™ variable-loop multielectrode catheter

Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan

09 January 2024

Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe